RE:INTERESTINGIf you read a little more about this you will find that the reason behind these findings is exactly why AcuVid could and should be a gamechanger.
The issue is one of sample type and location of predominant infection. Omicron most typically infects the upper respiratory tract while delta was deeper in the lungs. As such nasal swabs were least effective in detecting omicron and the recommendation was to swab the inside of the cheeks to improve sample collection when using the rapid antigen tests currently available. As has been clearly established with ALL of the testing Therma Bright has been forced to conduct this IS NOT an issue with AcuVid.
13X2413 wrote: In February, the Ontario COVID-19 Science Advisory Table published findings from an analysis of preprint studies suggesting that the pooled sensitivity of rapid antigen tests for detecting Omicron infections is about 37 per cent, compared to 81 per cent for the Delta variant.
Health Canada says on its website that it has "no evidence" that variants affect the ability of agency-approved tests to confirm COVID-19 cases, but notes that these new devices are still being investigated.